Warning! GuruFocus detected
5 Severe warning signs
with BNR.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Burning Rock Biotech Ltd
ISIN : US12233L1070
Share Class Description:
LSE:BNR: ADRDescription
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.94 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -5.98 | |||||
| Beneish M-Score | -3.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.5 | |||||
| 3-Year EBITDA Growth Rate | 27.4 | |||||
| 3-Year EPS without NRI Growth Rate | 29.1 | |||||
| 3-Year FCF Growth Rate | 50.9 | |||||
| 3-Year Book Growth Rate | -34.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.08 | |||||
| 9-Day RSI | 1.45 | |||||
| 14-Day RSI | 4.38 | |||||
| 3-1 Month Momentum % | -7.97 | |||||
| 6-1 Month Momentum % | -21.22 | |||||
| 12-1 Month Momentum % | -41.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | |||||
| Quick Ratio | 2.68 | |||||
| Cash Ratio | 1.95 | |||||
| Days Inventory | 155.93 | |||||
| Days Sales Outstanding | 104.12 | |||||
| Days Payable | 60.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | -13.12 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.26 | |||||
| Operating Margin % | -62.4 | |||||
| Net Margin % | -67.01 | |||||
| FCF Margin % | -17.98 | |||||
| ROE % | -50.84 | |||||
| ROA % | -35.07 | |||||
| ROIC % | -102.28 | |||||
| 3-Year ROIIC % | -118.34 | |||||
| ROC (Joel Greenblatt) % | -194.41 | |||||
| ROCE % | -44.42 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.65 | |||||
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.59 | |||||
| EV-to-EBIT | 0.4 | |||||
| EV-to-EBITDA | 0.4 | |||||
| EV-to-Revenue | -0.25 | |||||
| EV-to-FCF | 1.39 | |||||
| Price-to-GF-Value | 0.39 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 1.58 | |||||
| Earnings Yield (Greenblatt) % | 250 | |||||
| FCF Yield % | -27.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Burning Rock Biotech Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 71.615 | ||
| EPS (TTM) ($) | -3.099 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 43.53 | ||
| 14-Day RSI | 4.38 | ||
| 14-Day ATR ($) | 0.148442 | ||
| 20-Day SMA ($) | 5.40655 | ||
| 12-1 Month Momentum % | -41.77 | ||
| 52-Week Range ($) | 3.562 - 11.5 | ||
| Shares Outstanding (Mil) | 10.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Burning Rock Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Burning Rock Biotech Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Burning Rock Biotech Ltd Frequently Asked Questions
What is Burning Rock Biotech Ltd(LSE:BNR)'s stock price today?
The current price of LSE:BNR is $3.56. The 52 week high of LSE:BNR is $11.50 and 52 week low is $3.56.
When is next earnings date of Burning Rock Biotech Ltd(LSE:BNR)?
The next earnings date of Burning Rock Biotech Ltd(LSE:BNR) is 2025-05-29 Est..
Does Burning Rock Biotech Ltd(LSE:BNR) pay dividends? If so, how much?
Burning Rock Biotech Ltd(LSE:BNR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers